Akynzeo - (235 mg/20 mL and 0.25mg/20 mL ; Solution, Intravenous)

Generic Name	Fosnetupitant chloride hydrochloride; palonosetron hydrochloride	Innovator	HELSINN
Dosage	235 mg/20 mL and 0.25mg/20 mL ; Solution, Intravenous	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	AKYNZEO for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
***** ******	*** \ *********	*** **, ****	*******	****	******* *** **** *** *** ****

Chronology Of Events